Here is a quiz for the board. According to this q
Post# of 72436
![Avatar](/images/ProfileImages/1207987678_3042_Picture 5.jpg)
According to this quote from the 9/20 PR,notice the part that refers to additional funding,when available,work
will commence on developing an oral pill for Kevetrin.
See below:
“Near-term strategic clinical priorities remain: to work closely with the FDA and other regulatory
authorities to align on the remaining development plan necessary for Brilacidin in Oral Mucositis;
to analyze the Prurisol Phase 2b data in Psoriasis; and, as additional funding becomes available,
to commence work on new product formulations—1) an oral pill for Kevetrin in Ovarian Cancer;
2) an oral pill for Brilacidin in IBD; and a topical application for Brilacidin in Atopic Dermatitis and Acne.”
Now I don't think that ,even if IPIX had the entire 10MM from the MFO deal,they would be able to both keep the
company operating AND also complete the development and testing for Kevetrin Oral AND develop the oral pill for B IBD.
Soooooo where's the money coming from ?
I wouldn't think that Leo would presume on a deal if it hasn't been finalized yet and how would they secure the services
of a CRO without having some upfront cash on hand?
Did IPIX get additional funding from another source that we don't know about yet?
Has the BP deal been finalized?
In either case, each is a material event that would require filing an 8K within 4 days of the occurrence correct?
I also don't think that they are waiting for the IBD conference to sign and announce any partnership because that
would just leave the door open for another 3-4 weeks for someone to get "cold feet"and pull out.
I would be interested in what real and reliable longs here draw for conclusions.
Kelt
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)